Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Transarterial embolization with embozene microspheres (CeloNova BioSciences Inc.) for treatment of hepatocellular carcinoma and other liver tumors. Lansdale: HAYES, Inc.. Health Technology Brief Publication. 2013 Authors' conclusions Hepatocellular carcinoma (HCC) is primary cancer of the liver that accounts for more than 80% of all liver cancer types. Although HCC is uncommon in the United States, there are more than 1 million new cases diagnosed globally each year. HCC is an aggressive tumor that is one of the most common causes of cancer death worldwide. The overall 5-year survival rate for liver cancer is 15%. Signs and symptoms in the early stages of HCC are uncommon. Appropriate treatment for HCC depends upon the stage of disease. Only about 5% of patients are eligible for tumor resection, which is indicated in cases with solitary tumors that are confined to the liver and normal or well-preserved liver function. Patients with localized or locally advanced, unresectable cancer may be treated with liver transplantation. Most patients present with intermediate or advanced stage disease that is not amenable to curative treatments, such as liver transplantation. Local palliative therapies include percutaneous radiofrequency ablation, bland transarterial embolization (TAE), transarterial chemoembolization (TACE), drug-eluting bead TACE (DEB-TACE), radioembolization, or other forms of ablation. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver Neoplasms; Microspheres Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32014000405 Date abstract record published 21/02/2014 |